לובוב בלומקין

Prof. Dr. לובוב בלומקין

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2018 in Journal of Child Neurology
Verified
Journal Article
Closed access
SLStephanie Libzon
Stephanie Libzon
LSLihi Bar-Lev Schleider
Lihi Bar-Lev Schleider
NSNaama Saban
Naama Saban
LLLuda Levit
Luda Levit
YTYulia Tamari
Yulia Tamari
לבלובוב בלומקין
לובוב בלומקין
A complex motor disorder is a combination of various types of abnormal movements that are associated with impaired quality of life (QOL). Current therapeutic options are limited. We studied the efficacy, safety, and tolerability of medical cannabis in children with complex motor disorder. This pilot study was approved by the institutional ethics committee. Two products of cannabidiol (CBD) enriched 5% oil formulation of cannabis were compared: one with 0.25% δ-9-tetrahydrocannabinol (THC) 20:1 group, the other with 0.83% THC 6:1 group. Patients aged 1 to 17 years (n = 25) with complex motor disorder were enrolled. The assigned medication was administered for 5 months. Significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and QOL was observed in the total study cohort, regardless of treatment assignment. Adverse effects were rare and included worsening of seizures in 2 patients, behavioral changes in 2 and somnolence in 1.

1 May 2015 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
לבלובוב בלומקין
לובוב בלומקין
ELEsther Leshinsky-Silver
Esther Leshinsky-Silver
MMMarina Michelson
Marina Michelson
AZAyelet Zerem
Ayelet Zerem
SKSara Kivity
Sara Kivity
TLTally Lerman-Sagie
Tally Lerman-Sagie

1 January 2021 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
TGTamar Gur-Hartman
Tamar Gur-Hartman
OBOren Berkowitz
Oren Berkowitz
KYKeren Yosovich
Keren Yosovich
ARAgathe Roubertie
Agathe Roubertie
GZGinevra Zanni
Ginevra Zanni
לבלובוב בלומקין
לובוב בלומקין

1 May 2020 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
לבלובוב בלומקין
לובוב בלומקין
ZLZvi Leibovitz
Zvi Leibovitz
KKKarina Krajden-Haratz
Karina Krajden-Haratz
AAAyala Arad
Ayala Arad
KYKeren Yosovich
Keren Yosovich
TLTally Lerman-Sagie
Tally Lerman-Sagie

Verified
Journal Article
Open access
PDF file
PSPaula Sancho
Paula Sancho
AAAmparo Andres
Amparo Andres
NGNerea Gorría-Redondo
Nerea Gorría-Redondo
KLKatia Llano
Katia Llano
LMLola Martínez
Lola Martínez
SASergio Aguilera-Albesa
Sergio Aguilera-Albesa
(1) Background: A non-progressive congenital ataxia (NPCA) phenotype caused by β-III spectrin (SPTBN2) mutations has emerged, mimicking spinocerebellar ataxia, autosomal recessive type 14 (SCAR14). The pattern of inheritance, however, resembles that of autosomal dominant classical spinocerebellar ataxia type 5 (SCA5). (2) Methods: In-depth phenotyping of two boys studied by a customized gene panel. Candidate variants were sought by structural modeling and protein expression. An extensive review of the literature was conducted in order to better characterize the SPTBN2-associated NPCA. (3) Results: Patients exhibited an NPCA with hypotonia, developmental delay, cerebellar syndrome, and cognitive deficits. Both probands presented with progressive global cerebellar volume loss in consecutive cerebral magnetic resonance imaging studies, characterized by decreasing midsagittal vermis relative diameter measurements. Cortical hyperintensities were observed on fluid-attenuated inversion recovery (FLAIR) images, suggesting a neurodegenerative process. Each patient carried a novel de novo SPTBN2 substitution: c.193A > G (p.K65E) or c.764A > G (p.D255G). Modeling and protein expression revealed that both mutations might be deleterious. (4) Conclusions: The reported findings contribute to a better understanding of the SPTBN2-associated phenotype. The mutations may preclude proper structural organization of the actin spectrin-based membrane skeleton, which, in turn, is responsible for the underlying disease mechanism.

26 May 2018 in Neuropediatrics
Verified
Journal Article
Closed access
PDF file
TLTally Lerman-Sagie
Tally Lerman-Sagie
AWAna Westenberger
Ana Westenberger
HBHilla Ben-Pazi
Hilla Ben-Pazi
AZAyelet Zerem
Ayelet Zerem
KYKeren Yosovich
Keren Yosovich
לבלובוב בלומקין
לובוב בלומקין
Objective This article elucidates a clinical and genetic approach to pediatric early-onset chorea in patients with normal neuroimaging. Methods We retrospectively studied patients with onset hyperkinetic movement disorders. Only children with onset of chorea in the first 3 years of life were included, those with an abnormal magnetic resonance imaging (MRI) or electroencephalogram (EEG) were excluded. We studied the movement disorder phenotype by clinical examination and by interpretation of videos and compared our data to the literature. Results Four patients, aged 2 to 13 years, were diagnosed. Abnormal involuntary movements appeared between the ages of 6 months to 3 years in association with developmental delay. One patient has a close relative with NKX2.1-related chorea. One patient is from Iraqi-Jewish origin. Facial twitches and nocturnal dyskinetic attacks were observed in one. The unique clinical presentation and family history enabled genetic diagnosis by molecular analysis of a specific mutation in two (NKX2.1, OPA3) and Sanger sequencing of a target gene in one (ADCY5). One patient was diagnosed by whole-exome sequencing (WES) (GNAO1). Conclusion By carefully recording the phenotype and genetic background, a single gene can be suspected in some cases. In the rest, we suggest multigene panels or WES study.